Cargando…

Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais

OBJECTIVE: To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS: Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. A...

Descripción completa

Detalles Bibliográficos
Autores principales: da Silva, Roberta Barros, da Silva, Thales Philipe Rodrigues, Sato, Ana Paula Sayuri, Lana, Francisco Carlos Felix, Gusmão, Josianne Dias, Souza, Janaina Fonseca Almeida, Matozinhos, Fernanda Penido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculdade de Saúde Pública da Universidade de São Paulo 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522717/
https://www.ncbi.nlm.nih.gov/pubmed/34706042
http://dx.doi.org/10.11606/s1518-8787.2021055003734
_version_ 1784585149290119168
author da Silva, Roberta Barros
da Silva, Thales Philipe Rodrigues
Sato, Ana Paula Sayuri
Lana, Francisco Carlos Felix
Gusmão, Josianne Dias
Souza, Janaina Fonseca Almeida
Matozinhos, Fernanda Penido
author_facet da Silva, Roberta Barros
da Silva, Thales Philipe Rodrigues
Sato, Ana Paula Sayuri
Lana, Francisco Carlos Felix
Gusmão, Josianne Dias
Souza, Janaina Fonseca Almeida
Matozinhos, Fernanda Penido
author_sort da Silva, Roberta Barros
collection PubMed
description OBJECTIVE: To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS: Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. All suspected cases of AEFI of the covid-19 vaccine in the state were analyzed, totaling 7,305 cases. In this study, we verified the possible correlation between AEFI and the possible immunobiological administered causalities. The variables analyzed for AEFI cases were the immunobiological agent administered (AstraZeneca or Coronavac), the type of event, the evolution of the case, and the time in days since the administration of the immunobiological agent and the onset of symptoms and causality. The incidence rate (IT) was calculated for 100,000 doses applied. RESULTS: The occurrence of AEFI as a result of the covid-19 vaccine was frequent (TI: 777.12) in the state. However, only 3% were classified as a severe AEFI, with a 20.85 IT, and 4.71% of them evolved to deaths (8.19 deaths per 100,000 doses applied). Among the deaths analyzed, 84.4% were classified as preexisting conditions caused by factors other than vaccines. Regarding non-serious AEFI, 1.11% occurred by immunization errors (TI: 8.62 EI for every 100 thousand doses applied). CONCLUSION: This work encourages the discussion about the importance of recording AEFI related to covid-19 vaccines, demonstrating its safety for the population.
format Online
Article
Text
id pubmed-8522717
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Faculdade de Saúde Pública da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-85227172021-10-22 Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais da Silva, Roberta Barros da Silva, Thales Philipe Rodrigues Sato, Ana Paula Sayuri Lana, Francisco Carlos Felix Gusmão, Josianne Dias Souza, Janaina Fonseca Almeida Matozinhos, Fernanda Penido Rev Saude Publica Original Article OBJECTIVE: To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS: Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. All suspected cases of AEFI of the covid-19 vaccine in the state were analyzed, totaling 7,305 cases. In this study, we verified the possible correlation between AEFI and the possible immunobiological administered causalities. The variables analyzed for AEFI cases were the immunobiological agent administered (AstraZeneca or Coronavac), the type of event, the evolution of the case, and the time in days since the administration of the immunobiological agent and the onset of symptoms and causality. The incidence rate (IT) was calculated for 100,000 doses applied. RESULTS: The occurrence of AEFI as a result of the covid-19 vaccine was frequent (TI: 777.12) in the state. However, only 3% were classified as a severe AEFI, with a 20.85 IT, and 4.71% of them evolved to deaths (8.19 deaths per 100,000 doses applied). Among the deaths analyzed, 84.4% were classified as preexisting conditions caused by factors other than vaccines. Regarding non-serious AEFI, 1.11% occurred by immunization errors (TI: 8.62 EI for every 100 thousand doses applied). CONCLUSION: This work encourages the discussion about the importance of recording AEFI related to covid-19 vaccines, demonstrating its safety for the population. Faculdade de Saúde Pública da Universidade de São Paulo 2021-10-05 /pmc/articles/PMC8522717/ /pubmed/34706042 http://dx.doi.org/10.11606/s1518-8787.2021055003734 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
da Silva, Roberta Barros
da Silva, Thales Philipe Rodrigues
Sato, Ana Paula Sayuri
Lana, Francisco Carlos Felix
Gusmão, Josianne Dias
Souza, Janaina Fonseca Almeida
Matozinhos, Fernanda Penido
Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
title Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
title_full Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
title_fullStr Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
title_full_unstemmed Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
title_short Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
title_sort adverse events following immunization against sars-cov-2 (covid-19) in the state of minas gerais
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522717/
https://www.ncbi.nlm.nih.gov/pubmed/34706042
http://dx.doi.org/10.11606/s1518-8787.2021055003734
work_keys_str_mv AT dasilvarobertabarros adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais
AT dasilvathalesphiliperodrigues adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais
AT satoanapaulasayuri adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais
AT lanafranciscocarlosfelix adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais
AT gusmaojosiannedias adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais
AT souzajanainafonsecaalmeida adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais
AT matozinhosfernandapenido adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais